Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 2,928.2	$ 2,827.3	$ 8,207.0	$ 8,233.2
Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	456.8	466.7	1,289.6	1,471.6
Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	478.0	444.1	1,160.0	1,096.4
Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	473.3	304.0	1,299.7	956.8
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	230.8	284.1	633.8	832.2
Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	273.8	265.6	806.1	800.1
Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	194.4	212.6	644.5	648.6
Dermatology
Disaggregation of Revenue [Line Items]
Net sales	143.3	167.5	366.0	553.2
Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	187.0	172.5	500.2	529.0
Oncology
Disaggregation of Revenue [Line Items]
Net sales	260.9	221.1	734.7	533.5
Immunology
Disaggregation of Revenue [Line Items]
Net sales	42.9	20.3	100.3	72.5
Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	187.0	268.8	672.1	739.3
North America Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	155.5	154.7	426.4	554.2
North America Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	28.7	63.1	77.3	172.1
North America Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	308.5	161.8	805.3	457.3
North America Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	63.3	95.9	159.1	262.4
North America Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	30.0	24.5	94.9	102.5
North America Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	91.3	94.9	326.1	318.6
North America Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	38.2	86.7	77.6	265.7
North America Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	100.4	83.1	269.5	261.4
North America Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	196.1	171.0	567.8	382.5
North America Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	12.3	8.0	31.4	36.1
North America Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	64.3	68.6	199.6	185.6
Europe Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	214.3	219.6	619.3	665.7
Europe Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	179.0	157.8	299.7	280.5
Europe Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	98.2	94.8	327.9	351.8
Europe Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	126.2	147.3	358.6	443.2
Europe Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	147.9	150.0	434.9	448.3
Europe Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	68.9	73.9	208.0	227.9
Europe Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	75.8	62.8	217.7	217.4
Europe Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	60.5	61.3	165.3	198.1
Europe Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	22.0	18.2	59.9	55.4
Europe Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	20.3	2.3	41.3	7.3
Europe Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	32.8	53.3	198.1	174.7
Rest of World Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	87.0	92.4	243.9	251.7
Rest of World Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	270.3	223.2	783.0	643.8
Rest of World Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	66.6	47.4	166.5	147.7
Rest of World Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	41.3	40.9	116.1	126.6
Rest of World Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	95.9	91.1	276.3	249.3
Rest of World Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	34.2	43.8	110.4	102.1
Rest of World Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	29.3	18.0	70.7	70.1
Rest of World Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	26.1	28.1	65.4	69.5
Rest of World Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	42.8	31.9	107.0	95.6
Rest of World Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	10.3	10.0	27.6	29.1
Rest of World Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	89.9	146.9	274.4	379.0
Operating Segment | North America Segment
Disaggregation of Revenue [Line Items]
Net sales	1,088.6	1,012.3	3,035.0	2,998.4
Operating Segment | Europe Segment
Disaggregation of Revenue [Line Items]
Net sales	1,045.9	1,041.3	2,930.7	3,070.3
Operating Segment | Rest of World Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 793.7	$ 773.7	$ 2,241.3	$ 2,164.5